Forbes August 27, 2024
Niven R. Narain, Ph.D., President & CEO, BPGbio.
For the past several years, investors have flocked to biotech on the promise of AI to accelerate drug development, reduce costs and enhance predictability. The math was a no-brainer: Shaving just 10% off the drug development timeline could translate to hundreds of millions saved.
Many of these companies, however, didn’t deliver ROI as quickly as investors expected. Also, 56% of publically traded biotech companies had two or fewer years of cash in 2023, which also diminished investor expectations.
As the president and CEO of a biotech company that incorporates AI into every step of its drug development process, I have seen both the promise—and the limits—of AI. As I think about what...
Today's Sponsors
Today's Sponsor